Comparison of Outcomes and Surgical Time Between Cortical and Medullary Suture vs. Medullary-Only Suture: Cortex Clinical Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBrazilian Institute of Robotic Surgery

About this trial

Renal function preservation is a growing concern in the surgical management of kidney tumors, particularly with the rise in chronic kidney disease worldwide. Recent surgical innovations have focused on modifying renorrhaphy techniques to minimize renal damage. Emerging evidence suggests that omitting cortical suturing may reduce operative time, blood loss, and renal parenchymal loss without increasing major complications. This randomized controlled trial aims to compare outcomes between medullary-only and combined cortical-medullary suture techniques during robot-assisted partial nephrectomy, with the goal of identifying the approach that best balances functional preservation and surgical safety.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of renal mass confirmed by computed tomography (CT) or magnetic resonance imaging (MRI)

Indication for partial nephrectomy

Written informed consent

Expected survival of at least 6 months

Disqualifiers

Solitary kidney

Multiple or bilateral renal masses if more than one mass is operated on simultaneously or within less than 4 months

Hepatic or renal toxicity grade ≥ 2 with glomerular filtration rate (GFR) < 30 according to Common Terminology Criteria for Adverse Events (CTCAE v4)

Bleeding diathesis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Medullary-only suturing (single-layer)

    Procedure/Surgery

    Only the base layer (medulla) is sutured after tumor excision, Cortical suturing is omitted. Hemostatic agents are applied.

  • Suture

    Device

    Synthetic absorbable monofilament suture (Caproyl™ 3-0).

  • Medullary and cortical suturing (two-layer)

    Procedure/Surgery

    Both medullary and cortical layers are sutured after tumor excision, Performed with robotic assistance using absorbable sutures. Hemostatic agents are applied

  • Suture

    Device

    Synthetic absorbable monofilament suture (Caproyl™ 3-0), absorbable braided suture (Vicryl™ 0)

  • Hemostatic Agent

    Device

    Hemostatic agents (e.g., Bleed Stp Plus, Surgicel® Fibrillar, Hemopatch®).

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Medullary-only suturing (single-layer)Experimental treatment 3 interventions
Group B: Medullary and cortical suturing (two-layer)Active comparator 3 interventions

Trial outcomes

Primary outcomes

1

Estimated Blood loss

Estimated blood loss, assessed to compare renorrhaphy techniques (single medullary suture vs. combined medullary and cortical suture) during partial nephrectomy. The volume, recorded in milliliters, was measured using a graduated collection canister connected to the assistant surgeon's suction device, with correction for the amount of saline solution instilled into the cavity.

Time frame
Perioperative/Periprocedural time

Secondary outcomes

1

Change in estimated glomerular filtration rate (eGFR)

Difference in eGFR values calculated using the CKD-EPI formula between baseline (preoperative) and postoperative time points

Time frame
1 day, 2 weeks, 2 months, and 5 months
2

Percentage renal volume loss

Percentage reduction in renal parenchymal volume calculated from CT scan measurements at 4 months compared with baseline preoperative volume.

Time frame
4 months
3

Warm ischemia time

Duration, in minutes, of arterial clamping recorded during partial nephrectomy

Time frame
Perioperative/Periprocedural time
4

Participants with intraoperative or postoperative complications

Number of participants experiencing complications such as hematuria, pseudoaneurysm, or urinary fistula, graded according to the Clavien-Dindo classification.

Time frame
Through 5 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.